Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Clinuvel, de droom van elke belegger......
Volgen
info@tillema.rapide.nl schreef:
Op welke site vind ik de beurs van Frankfurt?
gewoon op de site van Binckbank. fondscode 107983 (even bij je favorieten zetten).
www.deutscheboerse.de wel zoeken op clinuvel en niet cuv anders krijg je een ander fonds. en als je de australische koers wilt volgen vanaf 23.00 uurwww.asx.com.au
De koers is flink teruggevallen maar dit was te verwachten... sommigen denken op korte termijn en geloven nog steeds op een high te kunnen verkopen en bij een low zich weer in kunnen kopen..... trend heet zoiets geloof ik..... ik zie uit naar nieuwe records op zeer korte termijn.
Opening min 11,11% naar 0,48 ; gaat lekker zo ! Maar weer eens bijgekocht op 0,50.
Gezien, op 0.49 krijg ik ze niet binnen.finance.yahoo.com/q?s=UR9.F
bertvv schreef:
Gezien, op 0.49 krijg ik ze niet binnen.
finance.yahoo.com/q?s=UR9.F Inmiddels binnen. Deze link is duidelijkerde.finance.yahoo.com/q?s=UR9.F
bertvv schreef:
[quote=bertvv]
Gezien, op 0.49 krijg ik ze niet binnen.
finance.yahoo.com/q?s=UR9.F [/quote]
Inmiddels binnen.
Deze link is duidelijker
de.finance.yahoo.com/q?s=UR9.F Dit is echter alleen maar de koers van Frankfurt. Via Xetra handel zijn er nog 156.000 verhandeld. Henks
min 0.06 -/- 11% weet iemand de reden? is er slecht nieuws ofzo?
jip banaan! schreef:
min 0.06 -/- 11%
weet iemand de reden? is er slecht nieuws ofzo?
Kan niets vinden. Laatste nieuws van bedrijf op 31.1 Momenteel 4 ct in de min. Mogelijk wat winstnemingen of. . Omzet gering.www.clinuvel.com.au/IRM/content/inves...
Inderdaad, winstnemingen waardoor de koers dik terugvalt. Echter deze maand zullen we de 60 eurocent drempel gaan nemen, dus nu een goed moment om in te stappen. Kijk niet alleen naar het aandeel op de frankfurter boerse maar ook in australie = asx en de verenigde staten. Dan pas kun je volumes gaan beoordelen.
De australische beurs staat nu alweer 2 cent hoger....een nieuwe aanloop naar hogere plafonds?
frank2you schreef:
De australische beurs staat nu alweer 2 cent hoger....een nieuwe aanloop naar hogere plafonds?
Je slaapt er wel van hoop ik he?
Hahaha...ja Bert...ik slaap goed....heb er het volste vertrouwen in dat dit een parel is die tot ongekende omgang kan groeien. Meld je aan op www.sharescene.com en dicussieer met de beleggers van het eerste uur in dit aandeel. Daartussen zitten mensen die meegedaan hebben aan de trials in Australie en ook mensen die persoonlijk kontakt hebben met de raad van bestuur. Erg interessant.
Merci, een van de redenen waarom ik direct ben ingestapt is dat dit aandeel jou reden geeft tot posten. Ruim 1000 dagen lid van IEX, 37 postings en al 11 aanbevelingen. Eigenlijk kun je dan wel blind instappen. CY tomorrow. Bert
Ok, was ik mezelf nog niet eens van bewust. Kom wel dagelijks kijken hier op IEX maar deed eigenlijk weinig mee aan discussies op het forum en al helemaal niet met de zogenaamde experts zoals Nikken en Co. Als je het zo goed weet hoef je geen loonslaaf meer te zijn is mijn mening maar goed. Wat clinuvel betreft....stabiel ronde de 50 eurocent. Weinig schokkend nieuws deze week. We wachten dit jaar op : - de ontwikkelingen van Fase III - de ontwikkelingen betr. de patenten. - het evt. samenwerken met een grote speler op de farm. markt. - het steeds meer bekendheid krijgen in de markt. Dus momenteel...geduld hebben en afwachten.
Koers is vandaag van 0,50 naar 0,58 gestegen. Iemand enig idee waarom ? Kan zelf geen echt nieuws ontdekken.
Beste Svenhedin, Dit heeft er alles mee te maken dat er op dit moment 2 keer zoveel vraag is dan aanbod...of met andere woorden.... de aanbieders kunnen hogere prijzen vragen. Nog kort geleden zakte de koers van 60 cent terug naar 50 omdat er heel veel winstnemingen waren....dus veel meer aanbod dan vraag...waardoor de prijs daalde. De 50 cent is een sterke bodem gebleken, de 60 cent een drempel die naar mijn mening volgende maand gepasseerd wordt. gr. Frank
Weer zeer goed nieuws. The only way is up. Clinuvel reports first positive Phase II clinical trial results of CUV1647 in new indication -EPP Clinuvel Pharmaceuticals Limited (ASX:CUV) is pleased to announce that a Phase II trial of CUV1647 met its endpoints in Erythropoietic Protoporphyria (EPP) patients. View Announcement Clinuvel Pharmaceuticals Limited is the new name for Epitan Limited.
Volledig artikel. Company Announcement Thursday 22nd February 2007 Melbourne, Australia Clinuvel reports first positive Phase II clinical trial results of CUV1647 in new indication - Erythropoietic Protoporphyria (EPP) Clinuvel Pharmaceuticals Limited (ASX:CUV) is pleased to announce that a Phase II trial of CUV1647 met its endpoints in Erythropoietic Protoporphyria (EPP) patients (see Appendix I). The preliminary results of this photo-provocation trial showed that CUV1647 significantly delayed or abrogated the onset of pain induced by light stimulation. Furthermore, additional anecdotal reports from the diaries of all patients indicated that they were able to expose themselves to sunlight, without suffering the characteristic pain of EPP. EPP is currently one of four key indications that Clinuvel is investigating to pursue market approval of CUV1647. With these favourable results, Clinuvel intends to advance to Phase III as soon as possible, pending regulatory approval. Background to the disease EPP is a genetic condition characterised by severe light-sensitivity (phototoxicity) of the skin. It is a rare disorder (caused by a fault in heme synthesis) that affects between one in 200,000 and 750,000 people. This condition mostly occurs in people with a fair-skinned complexion and is characterised by excruciating pain, swelling, and scarring (mostly hands and face). Typically, the pain experienced by these patients requires treatment with analgesics or antiinflammatory agents throughout their lives. EPP patients are often forced to remain shielded indoors, a lifelong behaviour that gravely affects their lives. Results The open label trial began in September 2006 at Triemli Hospital in Zürich, Switzerland. In the trial a controlled source of polychromatic light (light of multiple wavelengths) was used to emulate exposure of the skin to natural sunlight. Patients with clinically confirmed EPP were administered CUV1647 via two subcutaneous resorbable implants at two months intervals. In all 5 patients, the time to provoke pain (photoprovocation) was markedly prolonged (range: 384% - 1266%). The difference between the measurements of the photo-provocation times on days 0, 30, 60 and 90 days was statistically significant (p=0.0069). The increase in melanin density in EPP patients measured on days 0, 30, 60 and 90 (measured at six anatomical sites) yielded statistical significance (p=0.0029). Discussion of the results Despite the limited number of patients in this trial, significance was obtained which indicated the potential efficacy of CUV1647 as a photo-protective drug for EPP patients. This potential efficacy was confirmed by the diary reports of all 5 patients. As a result of this clinical outcome, Clinuvel has decided to advance its clinical program in EPP by conducting multicenter trials in the near future in both Europe and Australia. This decision will accelerate the development of CUV1647 by proceeding directly to a multicentre trial in EPP, under conditions of use, i.e. in spring and summer, when these patients suffer the most. Clinuvel’s CEO, Dr Philippe Wolgen said: “This is an important outcome for us as it is a preliminary demonstration of efficacy in a new clinical indication for the company. It is both promising and exciting that we may have demonstrated the potential to improve ‘quality of life’ in a group of patients who do not seem to have a remedy for their incapacitating disease. One should know that infants affected by EPP most often suffer an isolated childhood due to their undiagnosed, severe pain. It often takes years of suffering and withdrawal before their parents and physicians recognise EPP. Notwithstanding the encouraging outcome so far, this study was not placebo controlled. The conclusive evidence will only come when we administer the drug in the upcoming multicenter controlled trials, under environmental conditions during the seasons.” These trial results further add to the safety and efficacy profile of CUV1647.” Appendix I Following Code of Best Practice ASX Name of trial Phase II, Open Label Photo-provocation Study to Evaluate the Safety and Efficacy of Subcutaneous Resorbable Implants of CUV1647 in Patients with Erythropoietic Protoporphyria (EPP) Blinding status Open label study Treatment method, frequency, dose levels One 20 mg resorbable biocompatible implant of CUV1647 administered underneath the skin into the fatty region above the hip (iliac crest) every two months for a 12 month period (six doses in total). Number of subjects Nine * Subject selection criteria Patients aged 18 to 70 years who have been diagnosed with EPP. Primary endpoint 1. Time taken for the development of symptoms provoked during photoprovocation by a standardized light source (wavelength 380-650nm) onto the dorsum of the hand as predilection place and exposed area of the skin. Secondary Endpoints 2. The number and severity of phototoxic reactions; The level of melanin density in the skin (6 areas measured); The quality of life. Safety and tolerability. * Following efficacy found in the first 5 patients treated, it was decided to terminate this Phase II trial and accelerate the development of CUV1647 by applying for permission to advance to an expanded multicentre trial in EPP trial to be conducted in Europe and Australia. The remaining 4 patients of the trial in Zürich are likely to be enrolled in the Phase III study (pending on regulatory approval). Trial location Triemli Hospital, Birmensdorferstrasse 497, CH-8063 Zürich, Switzerland About Clinuvel Pharmaceuticals Limited Clinuvel Pharmaceuticals Limited (ASX:CUV) is an Australian biopharmaceutical company developing its leading drug CUV1647 for the treatment of UV-related skin disorders. Clinuvel’s pioneering work aims to assist in preventing the global problem of UV related skin disorders, by developing CUV1647 in areas of unmet medical need. Phase I and II human clinical trials using CUV1647 have demonstrated that it is well tolerated and no significant safety concerns have been identified to date. Clinuvel is presently preparing to start further Phase II and begin Phase III clinical trials, with a view to complete them in 2009. Over the next few years and following completion of the clinical development program, Clinuvel will work closely with global regulators to facilitate market approval of CUV1647. For more information contact: Kate Liscombe, Investor Relations Clinuvel Pharmaceuticals Limited, Tel: +61 3 9660 4900investorrelations@clinuvel.com -End- Clinuvel is an Australian biopharmaceutical company focussed on developing its leading drug candidate, CUV1647, for a range of UV-related skin disorders resulting from exposure of the skin to harmful UV radiation. Pharmaceutical research and development involves long lead times and significant risks. Therefore, while all reasonable efforts have been made by Clinuvel to ensure that there is a reasonable basis for all statements made in this document that relate to prospective events or developments (forward-looking statements), investors should note the following: • actual results may and often will differ materially from these forward-looking statements; • no assurances can be given by Clinuvel that any stated objectives, outcomes or timeframes in respect of its development programme for CUV1647 can or will be achie
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
887,44
+0,99%
EUR/USD
1,0762
+0,34%
FTSE 100
8.213,49
+0,51%
Germany40^
18.017,10
+0,67%
Gold spot
2.301,75
0,00%
NY-Nasdaq Composite
16.156,33
+1,99%
Stijgers
Dalers